Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
NCT05651828Phase 1Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2023
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vismodegib in basal cell carcinoma (BCC) (4 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Time to Treatment Failure at 36 months. Started Mar 2023; status: recruiting.
02
Drugs
vismodegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT05651828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651828.